Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.38 |
| ▸ | CNR2 | P34972 | 6/20 | 0.37 |
| ▸ | CNR1 | P21554 | 5/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
| ▸ | ADA | P00813 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22140236 | 0.83 | CNR2 (0.37) | KDRCNR2CNR1 | |
| SCHEMBL22140185 | 0.82 | CNR2 (0.34) | CNR2CNR1 | |
| SCHEMBL22140239 | 0.82 | CNR2 (0.37) | CNR2CNR1 | |
| SCHEMBL22140359 | 0.82 | CNR2 (0.34) | CNR2CNR1 | |
| SCHEMBL21719975 | 0.81 | CNR2 (0.38) | KDRCNR2CNR1 | |
| SCHEMBL21159335 | 0.81 | KDR (0.34) | KDRCNR2CNR1 | |
| SCHEMBL21719972 | 0.80 | CNR2 (0.35) | KDRCNR2CNR1 | |
| SCHEMBL21718603 | 0.80 | CNR2 (0.37) | KDRCNR2CNR1 | |
| SCHEMBL21719965 | 0.80 | CNR2 (0.35) | KDRCNR2CNR1 | |
| SCHEMBL21719974 | 0.80 | CNR2 (0.35) | KDRCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875839-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | KDR 1432/4885CNR2 443/4885CNR1 556/4885 |
| US-10875839-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | KDR 1432/4885CNR2 443/4885CNR1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.